주식/증권
📉 부정적
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
요약
Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global